The Austrian biotech Hookipa expects to raise €75M ($84M) in an IPO on the Nasdaq stock exchange to fund the phase II development of a vaccine for the virus cytomegalovirus, and the first clinical trials of its cancer vaccines.
News
Australian Biotech Hookipa is about to raise a 75M € IPO on Nasdaq for their counter viral and cancer vaccines
